Disease relevance of parC

• Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii [1].

High impact information on parC

• Moreover, the mechanisms of resistance to some beta-lactam antibiotics may be associated with the presence of a chromosomal cephalosporinase, AmpC, and the resistance to quinolones related to mutations in the gyrA and parC genes [2].
• Novel gyrA and parC point mutations in two strains of Acinetobacter baumannii resistant to ciprofloxacin [3].
• Mutations in both gyrA and parC were necessary for resistance to moxifloxacin in most isolates of A. baumannii [4].
• In strains with a single mutation at amino acid codon Ser83 of the gyrA gene, the MIC of clinafloxacin ranged from 0.12 to 1 mg/L, whereas strains with a double mutation, one in the gyrA gene and another in the parC gene, showed a range of MIC of clinafloxacin from 1 to 8 mg/L [5].
• Our studies highlight the conserved sequences in the quinolone-resistance-determining region of the parC gene from A. baumannii and other bacteria [1].

Biological context of parC

• The gyrA and parC genes were sequenced and the adeB gene examined by real-time reverse transcription PCR (RT-PCR) [6].

Associations of parC with chemical compounds

• The objective of this study was to analyse an array of ciprofloxacin and norfloxacin derivatives in order to determine those with good activity against bacteria that already present fluoroquinolone resistance associated with mutations in the gyrA and/or parC genes [7].
• Single mutations in both the gyrA and parC genes at codons Ser-83 and Ser-80, respectively, were found in ciprofloxacin- and moxifloxacin-resistant isolates [4].
• The MIC of clinafloxacin for strains with no mutation in either gyrA or parC genes ranged from 0.008 to 0.25 mg/L [5].

Analytical, diagnostic and therapeutic context of parC

• PCR analysis was used to detect chromosomal mutations in the gyrA and parC genes [4].

References